What If Better Onboarding Was the Key to Unlocking Adherence…and Access?

This Insider session brings together senior pharma leaders and digital innovators to explore a shared challenge: how to support patients on self-injection therapies in a way that drives real behavior change and business impact.

As self-injection becomes standard for chronic disease management, inconsistent onboarding remains a quiet barrier to both patient success and commercial performance. Patients who lack confidence often delay initiation, abandon early, or administer incorrectly—all of which directly affect adherence, persistence, and access outcomes.

Drawing on real-world data and program experience, this session will focus on the practical conditions needed to scale high-impact patient engagement initiatives across European markets.

Key Discussion Topics:

• Why Onboarding Matters More Than Ever – We’ll look at how poor onboarding affects dose initiation and adherence—and why brand, market access, and patient service leaders need a shared strategy to improve patient confidence from the start.

• Evidence That Moves the Needle – New findings from the U.S.-based Patient Engagement study show how structured onboarding and training improve patient confidence, reduce abandonment, and increase correct device use, results with direct commercial and clinical value.

• Getting Beyond Pilots: What It Takes to Scale – We’ll discuss scalable implementation pathways, across distribution channels, regions, and partners, along with sustainable business models that meet pharma, payer, and health system expectations.

• A Connected Approach to Patient Empowerment – Explore how Noble’s hands-on training solutions and Aptar Digital Health’s digital engagement tools work together to create a seamless, validated, and measurable self-injection experience.